miRNA-21 is developmentally regulated in mouse brain and is co-expressed with SOX2 in glioma by Jelena Põlajeva et al.
Põlajeva et al. BMC Cancer 2012, 12:378
http://www.biomedcentral.com/1471-2407/12/378RESEARCH ARTICLE Open AccessmiRNA-21 is developmentally regulated in mouse
brain and is co-expressed with SOX2 in glioma
Jelena Põlajeva1, Fredrik J Swartling1, Yiwen Jiang1, Umashankar Singh1, Kristian Pietras2, Lene Uhrbom1,
Bengt Westermark1* and Pernilla Roswall1,2*Abstract
Background: MicroRNAs (miRNAs) and their role during tumor development have been studied in great detail
during the last decade, albeit their expression pattern and regulation during normal development are however not
so well established. Previous studies have shown that miRNAs are differentially expressed in solid human tumors.
Platelet-derived growth factor (PDGF) signaling is known to be involved in normal development of the brain as well
as in malignant primary brain tumors, gliomas, but the complete mechanism is still lacking. We decided to
investigate the expression of the oncogenic miR-21 during normal mouse development and glioma, focusing on
PDGF signaling as a potential regulator of miR-21.
Methods: We generated mouse glioma using the RCAS/tv-a system for driving PDGF-BB expression in a cell-
specific manner. Expression of miR-21 in mouse cell cultures and mouse brain were assessed using Northern blot
analysis and in situ hybridization. Immunohistochemistry and Western blot analysis were used to investigate SOX2
expression. LNA-modified siRNA was used for irreversible depletion of miR-21. For inhibition of PDGF signaling
Gleevec (imatinib mesylate), Rapamycin and U0126, as well as siRNA were used. Statistical significance was
calculated using double-sided unpaired Student´s t-test.
Results: We identified miR-21 to be highly expressed during embryonic and newborn brain development followed
by a gradual decrease until undetectable at postnatal day 7 (P7), this pattern correlated with SOX2 expression.
Furthermore, miR-21 and SOX2 showed up-regulation and overlapping expression pattern in RCAS/tv-a generated
mouse brain tumor specimens. Upon irreversible depletion of miR-21 the expression of SOX2 was strongly
diminished in both mouse primary glioma cultures and human glioma cell lines. Interestingly, in normal fibroblasts
the expression of miR-21 was induced by PDGF-BB, and inhibition of PDGF signaling in mouse glioma primary
cultures resulted in suppression of miR-21 suggesting that miR-21 is indeed regulated by PDGF signaling.
Conclusions: Our data show that miR-21 and SOX2 are tightly regulated already during embryogenesis and define
a distinct population with putative tumor cell of origin characteristics. Furthermore, we believe that miR-21 is a
mediator of PDGF-driven brain tumors, which suggests miR-21 as a promising target for treatment of glioma.
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Despite the discovery and extensive studies of a large num-
ber of microRNAs (miRNAs), the role and molecular
mechanisms of their actions are still unclear [1]. miRNAs
have been shown to be involved in tumor development [2,3].
The expression pattern and signature of certain miRNAs are
important for the regulation of cell fate [4,5], and their ex-
pression signature has been shown to correlate with tumor
initiation and progression indicating a prognostic and diag-
nostic potential [6,7]. We have focused on miR-21 that re-
cently was identified as differentially expressed in a high
number of solid tumors when comparing to normal tissue
[8]. In addition miR-21 has been demonstrated to be up-
regulated in a majority of human cell lines and tumor tissues
such as glioblastoma [9], breast cancer [10], and chronic
lymphocytic leukemia [11]. Based on knockdown studies, it
has been proposed that miR-21 acts as an oncogene exerting
its effect by down-regulating crucial apoptosis-related genes
[9]. Furthermore, gain of function and loss of function of
miR-21 in a transgenic mouse model for non-small-cell lung
cancer showed that miR-21 behaved as a tumor promoter
[12]. Likewise, in a transgenic mouse model for conditional
expression of miR-21, a complete regression of B-cell lymph-
oma was observed upon withdrawal of miR-21 [13].
Glioblastoma multiforme (GBM) is the most frequent
and most malignant (grade IV) form of adult glioma. GBMs
are highly invasive and the median survival after diagnosis
ranges from 9 months to 2 years [14,15]. Like in all cancers,
glioma development is associated with uncontrolled prolif-
eration and escape of regulatory control of the cell cycle
[16]. Astrocytic gliomas of various grades have been shown
to overexpress platelet-derived growth factor receptor alpha
(PDGFR-α), whereas both PDGF-AA and PDGF-BB have
been consistently found in high grade gliomas (grade III
and IV) only, generating autocrine stimulation [17]. Despite
the extensive increase in knowledge in the past decade, the
clinical outcome of human gliomas has remained constant,
rationalizing the need for further studies.
In general, there is a lack of knowledge concerning the ex-
pression and function of miRNAs during normal develop-
ment. We decided to investigate the expression of miR-21
during normal brain development in mice. Interestingly,
miR-21 was indeed shown to be expressed already at embry-
onic day E18, displaying a sustained expression also in the
newborn brain. This expression was in some defined areas
overlapping with SOX2 expressing cells. miR-21 and to a
large extent also SOX2 expression were lost in the adult
brain, indicating a co-regulation. However, mouse gliomas
show high expression of miR-21. Furthermore, inhibition of
PDGF signaling using Imatinib (Gleevec), Rapamycin and
U0126, significantly reduced miR-21 levels in mouse glioma
primary cultures. Upon siRNA-mediated knockdown of
miR-21, the levels of SOX2 in both mouse glioma cell lines
and human glioblastoma cell lines strongly decreased. Thiswas further strengthened by in situ hybridization on mouse
brains revealing that the expression pattern of miR-21 was
specific to tumor areas and strongly overlapped with areas
staining positive for SOX2. Our data propose that the em-
bryonic expression pattern of miR-21 is maintained or re-
established during initiation and progression of glioblastoma.
Methods
Ethics Statements
All animal experiments were approved (ethical approval
number C18/6, 2006-02-24) and performed in accordance
with the rules and regulations of the Ethical Committee for
Animal Experiments in Uppsala (Sweden). Patient samples
were obtained following approval by the Regional Ethical
Review Board in Uppsala (ethical approval number 2007/
353, 2008-03-12). Patients provided written informed con-
sent for the collection of samples.
Cell culture and tumor samples
Human glioma cell lines U343MG, Cl2:6, U87MG,
U1242MG, U251MG, U373MG, U2987MG were previously
established in our laboratory [18-20]. Cells were cultured in
Minimum Essential Medium (MEM) supplemented with
10% fetal bovine serum (FBS), 2 mM L-glutamine and 100
units/ml penicillin and 0.1mg/ml streptomycin (Sigma
Aldrich, St Louis, MO).
Mouse glioma cell cultures were established from RCAS/
PDGFB-induced gliomas in a wild type, p16Ink4a−/−, p19Arf−/−
or p16Ink4a−/−/p19Arf−/− background [21-27]. The t-va retro-
viral receptor is expressed in transgenic mice under the con-
trol of the nestin or the GFAP promoter, addressing neural/
glial progenitor cells and astrocytes, respectively. In brief, an
immortalized chicken fibroblast cell line, DF1 (American
Type Culture Collection), producing RCAS/PDGF-B virus
particles, was injected intracerebrally in newborn mice
[28,29]. At sign of brain tumor, mice were euthanized and
the brains were aseptically dissected out. The brains were
cut with a coronal section at the injection site, and the anter-
ior part was mechanically disrupted and used for establishing
cell cultures whereas the posterior part was formalin-fixed
and used for paraffin sectioning. The mouse glioma cells,
the human fibroblast cell line 1064SK and LN18 gli-
oma cells [30], kindly provided Dr Nicolas de Tribolet,
Lausanne University, were cultured in Dulbeco’s Modified
Essential Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 4mM L-glutamine and 100 units/ml
penicillin and 0.1 mg/ml streptomycin (Sigma Aldrich).
All cells were grown at 37°C with 5% CO2. Embryos were
collected, formalin-fixed and paraffin embedded.
Human and mouse glioma-derived cancer-initiating cell
(GICs) cultures
Low passage human glioma cell culture U3001MG was re-
cently established in our group [31]. Fresh tumor samples
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The tumor was graded at the Uppsala University Hospital by
a neuropathologist according to World Health Organization
(WHO) guidelines. After the primary sphere formation,
the spheres were seeded onto dishes coated with ECM gel
(Sigma Aldrich) and cultured as adherent cells as described
before [32] in complete BTIC media, containing DMEM/
F12 Glutamax (GIBCO/Invitrogen, Carlsbad, CA), 10mM
HEPES (Sigma Aldrich), 25 μg/ml insulin, 100 μg/ml trans-
ferrin, 20 nM progesterone, 10 μM putrescine, 30 nM sel-
enite, 1% B27 (Invitrogen), 100 units/ml penicillin and 0.1
mg/ml streptomycin (Sigma Aldrich), 20 ng/ml EGF and
FGF2 (Peprotech Rocky, Hill, NJ, USA).TC1, low passage
mouse glioma-derived cancer-initiating cells (GICs) were
recently established in our lab, these were cultured in
complete BTIC media, excluding EGF and FGF, as neuro-
spheres [33].
RNA preparation
After starvation in serum-free media, 1064SK cells were
treated with PDGF-BB (10 mg/ml). Unless otherwise stated,
total RNA was extracted from human and mouse cell lines
using TRIzol reagent (Invitrogen) according to the manu-
facturer’s instructions. In short, cells were washed with
PBS, scraped off and spun down. The pellet was subjected
to TRIzol reagent and homogenized before chloroform ex-
traction. RNA was precipitated with isopropanol and
washed in 70% EtOH, before being eluted in DEPC-H2O.
After starvation in serum-free media, Nestin p19Arf−/− cells
were treated with the following inhibitors for 24 hours (h):
Imatinib mesylate (20 μM, BioVision, Mountain View, CA),
UO126 (10 μM, Cell Signaling Technology, Danvers, MA),
LY294002 (10 μM, Cell Signaling Technology), Rapamycin
(100 nM, Cell Signaling Technology). Following inhibition of
PDGF signaling, small RNA fraction was extracted using
MirVana Isolation Kit (Applied Biosystems, Carlsbad, CA)
according to manufacturer’s instructions. Briefly, cell lysate
was once extracted with Acid-Phenol:Chloroform and fur-
ther enriched for the small RNA fraction over a glass-fiber
filter. Finally, the RNA was eluted in DEPC-H2O containing
1% elution solution provided with the kit.
In situ hybridization
After deparaffinization of coronal sections of mouse brain,
the tissues were subjected to pepsin (1.3 mg/ml, Sigma
Aldrich) for 30 min. After washing in PBS the slides were
submerged in 99.7% ethanol and air-dried. Hybridization
was performed in a humidified chamber at 37°C for 16-18 h,
with a digoxigenin-labelled locked nucleic acid (LNA)
modified oligonucleotide (Integrated DNA Technologies,
Leuven, Belgium) diluted in Enzo In situ-hybridization buf-
fer (Enzo Life Sciences, Inc., Farmingdale, NY) to the con-
centration of 2 pmole/μl. After hybridization, slides were
rinsed at 4°C in washing buffer (Enzo Life Sciences, Inc.)and subjected to anti-digoxigenin alkaline phosphatase Fab
(Roche, Basel, Switzerland) at 37°C for 30 min. After incu-
bation in AP detection reagent (Enzo Life Sciences, Inc.)
the slides were incubated with NBT/BCIP reaction mixture
(Enzo Life Sciences, Inc.) in a humidified chamber at 37°C.
The slides were counterstained with Red counter stain
(Enzo Life Sciences, Inc.) and then washed in PBS, 100%
Ethanol and Xylene. The slides were mounted in Pertex
(Leica Microsystems, Kista, Sweden).
Transfections
LNA modified antisense miR-21 (5´-TCAACATCAGTC
TGATAAGCTA-3´) and antisense enhanced green fluores-
cence protein (EGFP) (5´-AAGGCAAGCUGACCCUGAA
GU-3´) used as a negative control, were purchased from
Integrated DNA Technologies. Cells were subconfluently
seeded in petri-dishes in antibiotic-free culture media.
Twenty-four hours after seeding the cells were transfected
with 50 nM LNA-miR-21 and si-EGFP with Lipofectamine
RNAiMAX (Invitrogen, San Diego, CA) in serum-free
medium. After 6 h the culture medium was changed to regu-
lar medium containing antibiotics and serum. Forty-eight
hours after transfection, the cells were collected for RNA ex-
traction. Cells were transfected with control siRNA or siRNA
against human PDGF-BB (Dharmacon, Lafayette CO) at a
concentration of 50 nM using Dharmacon 2 (Dharmacon).
Seventy-two h post transfection, cells were collected. Trans-
fection efficiency was determined to be significant using
quantitative real-time PCR as previously described [34].
Human PDGFB expression was normalized to mouse Hprt
(data not shown).
Northern blot analysis
Samples of total RNA (5-10 μg/lane) were electrophoresed
on a 15% TBE-Urea gel (NuPAGE, Invitrogen, San Diego,
CA) under denaturing conditions according to the protocol
supplied by the distributor. The RNA was transferred to a
Hybond N+ membrane (GE Healthcare, Uppsala, Sweden).
Hybridization was performed using 10 mM Na2HPO4,
10 mM NaH2PO4, 0.75 M NaCl, 75 mM Sodium Citrate,
0.02% Albumin, 7% SDS, 0.02% Ficoll 400 solution. miR21
or U6 snRNA DNA oligos were labeled in the 5´ end with
[γ-32P]ATP using T4 Polynucleotide Kinase (New England
Biolabs, Ipswich, MA), purified with G-25 MicroSpin Col-
umns (GE Healthcare) and used in the hybridization step
(42°C, 16-18 h). After being washed in 2xSSC 0.1% SDS the
membrane was exposed to an X-ray film (Hyperfilm ECL,
Amersham Biosciences).
Quantitative real-time PCR
Stem-loop reverse transcription for miR-21 was performed
using TaqManW MicroRNA Reverse Transcription Kit
according to manufacturers’ description (Applied Biosystems,
Carlsbad, CA). In short, RNA was reverse transcribed into
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using Stratagene Mx 3001P (Stratagene, La Jolla, CA) and
TaqManWMicroRNA Assays for miR-21 together with the
TaqManW Universal PCR Master Mix (Applied Biosystems).
All samples were run in triplicates for 45 cycles in a two-
step PCR at 95°C and 60°C. To calculate relative gene
expression, the comparative threshold cycle (CT) method
2-ΔΔCT was applied where CT is defined as the fractional
cycle number at which the fluorescence passes the fixed
threshold [35]. Values of miR-21 were normalized to ex-
pression of miR-16 (set to 1), and the relative expression
was quantified. U6 was also used as a control gene, showing
similar results as miR-16.
Immunoblot analysis
Cells were subjected to a lysis buffer (1% Triton X-100,
150 mM NaCl, 10 mM Tris–HCl pH 7.4, 1 mM EGTA,
1 mM EDTA, 0.5% NP-40, 35 ng/ml phenylmethylsulpho-
nyl fluoride, 1.4 μg/ml aprotinin, 1 mM Na3VO4, 1 mM
ZnCl2, 50 mM Na2MoO4). Protein concentration was
determined using BSA Protein Assay according to the
manufacturer´s instructions (Pierce Chemical Co, Rockford,
IL). Protein samples (5-10 μg per lane) were subjected to a
sodium dodecyl sulphate-polyacrylamide gel electrophor-
esis (SDS-PAGE; NuPAGE 4-12% Bis-Tris Gel, Invitrogen)
according to the protocol supplied by the distributor. Pro-
teins were transferred to a nitrocellulose filter (Hybond
ECL, Amersham Biosciences, Uppsala, Sweden). The filters
were blocked and subjected to antibodies in 5% dry milk in
TBS-T (10 nm Tris-base, 0.15 M NaCl, pH 7.7 and 0.1%
Tween). Filters were developed using substrate solution
(Chemoluminiscence, Super Signal, Pierce Chemical Co.)
on x-ray films (Hyperfilm ECL, GE Healthcare). The anti-
bodies used were: Cleaved Caspase-3 (Asp175) (Cell Signal-
ing Technology), GAPDH (Cell Signaling Technology,
Danvers, MA), SOX2 (Abcam, USA). Before being used
again the filters were stripped in a solution containing 100
mM β-mercaptoethanol, 2% SDS and 62.5 mM Tris–HCl
at pH 6.7.
Immunohistochemical analysis
Paraffin embedded mouse brains were sectioned in 5 μm
and adhered to glass slides, deparaffinized and pressure
boiled in citric buffer. Ultra Vision LP detection system
(Thermo Fisher Scientific, Fremont, CA) was used accord-
ing to manufacturer’s instructions. Briefly, slides were incu-
bated with Hydrogen Peroxidise Block, followed by Ultra V
Block treatment. Antibodies were diluted in 5% normal
goat serum and incubated over night (rabbit anti-mouse
SOX2 and rabbit anti-mouse OLIG2 (Millipore, Billerica,
MA). Primary antibody enhancer, HRP polymer and DAB
Plus Chromogen were used to visualize the staining. Slides
were counterstained with hematoxylin and mounted using
Immu-mount (Thermo Fisher Scientific, Fremont, CA).Images were taken using a Zeiss Observer Z1 microscope
and an AxioCam HRc Zeiss camera.
AnnexinV analysis
Cells cultured in duplicates in two individual experiments
were treated with LNA-miR-21 or si-EGFP (previously
described) for 48 h counting from addition of the si-RNA.
All cells, attached and detached were collected and washed
in PBS. To investigate apoptosis annexinV Alexa FluorW647
in combination with PI were added (VybrantW Apoptosis
Assay Kit, Molecular ProbesTM Invitrogen detection tech-
nologies). Apoptosis was analyzed by flow cytometry (BD
FACSTM LSRII).
Statistical analysis
Statistical significance was calculated using double-sided
unpaired Student´s t-test. Significance was calculated from
two independent experiments in the PDGFR signaling in-
hibitory trial and five independent experiments in the si-
PDGF-BB trial. The measurements are presented as mean
fold changes ± standard error of the mean (SEM).
Results
miR-21 is expressed during brain development but is
absent in adult brain
To investigate the involvement of miR-21 during embryo-
genesis we analyzed its expression pattern in the developing
mouse brain, using Gtv-a wild type mice. Coronal tissue
sections of paraffin embedded normal brain from embry-
onic day 18 (E18), were subjected to in situ hybridization,
which revealed that miR-21 was highly expressed in the
hippocampus and the outer rim of the cortex (containing
martinotti, pyramidal, and stellate cells) as shown in
Figure 1A. High expression was also found in the same
areas in newborn mouse brain (Figure 1B). However, at
postnatal day 7 (P7) and onwards miR-21 expression was
strongly reduced and no expression was found in the adult
brain (Figure 1C, and data not shown). miR-29b was used
as an independent control miRNA. Thus, miR-21 expres-
sion appears to be developmentally regulated and absent in
adult brain tissue.
Expression of SOX2 overlaps with miR-21 expression
during embryogenesis
Knowing that SOX2 is required to maintain cellular pluri-
potency in the developing embryo [36], we decided to in-
vestigate the expression pattern of miR-21 during mouse
brain development in relation to SOX2 expression, using
Gtv-a wild type mice. We used immunohistochemical
(IHC) staining and in situ hybridization to demonstrate that
SOX2 and miR-21 showed overlapping expression at E18
and P1 (Figure 2A, 2B). Dorsal lateral geniculate nucleus
(dLG) and dentate gyrus (DG) represent areas with a large
percent of double positive cells. However, a heterogeneity
Figure 1 miR-21 is expressed during embryonic development. In situ hybridization with a digoxigenin-labeled probe, showing differential
expression of miR-21 in normal E18 (A), newborn (P1) (B) and P7 (C) Gtv a wild type mouse brain. miR-21 could be seen in hippocampus as well
as areas close to the ventricle. A digoxigenin miR-29b was used as an independent miRNA control. Scale bar is indicated in the figure and
represents 50 μm.
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the ventral lateral geniculate nucleus (vLG) that are nega-
tive for SOX2, as previously described [37], but positive for
mir-21. The expression of SOX2 as well as miR-21 was sub-
stantially decreased at P7 (Figure 2C), also indicating a co-
regulation.
miR-21 is highly expressed in mouse glioma cells and
tissue
Previous studies describing miR-21 as an oncogene [3]
prompted us to generate experimental gliomas using the
RCAS/tv-a mouse model system [28]. Through intracerebral
injection of cells producing RCAS/PDGF-B virus, gliomas
were induced in a cell specific manner in newborn Ntv-a
and Gtv-a mice with either wild type, p16Ink4a−/−, p19Arf−/−
or p16Ink4a−/−/p19Arf−/− background. The PDGFB-induced
gliomas are generated by an autocrine/paracrine stimulation
and expansion of PDGFR-α positive glial progenitor/neural
stem cells present in the newborn mouse brain [38,39]. We
hypothesize that the aberrant expression of miR-21 in glioma
cells may exist in the normal progenitor and become re-
activated when that cell is targeted for tumor development,
knowing that some features of embryogenesis are recapitu-
lated in the tumor setting. As in previous studies [40] tumors
mimicking human gliomas appeared after four to twelveweeks, depending on the genetic background of the mouse.
Primary mouse glioma cell cultures were established and
Northern blot analysis showed that expression levels of miR-
21 varied between these cultures, although they all showed
an increased level as compared to normal mouse brain
(Figure 3A). The p16Ink4a−/− cells had the highest expression,
p19Arf−/− the lowest, whereas an intermediate expression was
found in wild type cells. Double knockout for both tumor
suppressors, p16Ink4a and p19Arf, had similar expression as
p16Ink4a single knockout (data not shown). To further inves-
tigate the expression pattern of miR-21 in vivo, coronal tissue
sections from paraffin embedded tumor-bearing Gtv-a
p16Ink4a−/−/p19Arf−/− mouse brains were subjected to in situ
hybridization. miR-21 positive cells were restricted to the
tumor areas, showing no expression in the adjacent normal
cells (Figure 3B and 3C).
Overlapping expression pattern of miR-21 and SOX2 in
mouse glioma
Encouraged by our previous finding of the overlapping ex-
pression pattern of miR-21 and SOX2 in the normal devel-
oping mouse brain, we performed IHC staining of mouse
glioma. It showed that the previously observed overlap of
miR-21 and SOX2 expression was even more pronounced,
exhibiting a total overlap in the tumor area (Figure 3C). On
Figure 2 Overlapping expression of SOX2 and miR-21. IHC and in situ hybridization showing the expression pattern of SOX2 and miR-21,
respectively. miR-21 expression in Gtv a wild type mouse brain at different developmental stages E18 is shown in A), P1 in B) and P7 in C). Scale
bar is indicated in the figure and represents 50 μm. Arrow indicates overlapping expression of SOX2 and miR-21. Abbreviations: dorsal lateral
geniculate nucleus (dLG), ventral lateral geniculate nucleus (vLG), dentate gyrus (DG).
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see that SOX2 was also co-expressed with OLIG2
(Figure 4A), which is a surrogate marker for brain tumor
cells [41,42].
miR-21 knockdown is followed by a decrease in SOX2
expression
To investigate the interplay between miR-21 and SOX2 fur-
ther we performed a target screen based on bioinformatics
(www.TargetScan.org) which suggested SOX2 to be a po-
tential target of miR-21 as opposed to our in vivo finding of
an overlapping expression pattern. We next analyzed the ef-
fect of miR-21 on SOX2 in p19Arf−/− mouse glioma primary
cultures after repression of miR-21 using locked nucleic
acid (LNA)-modified antisense miR-21. Suppression of
miR-21 resulted in a decrease of SOX2 in glioma cell cul-
tures derived from both Gtv-a and Ntv-a mice (Figure 4B).
We therefore conclude that miR-21, directly or through an
intermediate target, participates in the up-regulation of
SOX2 in these cells.
PDGF-BB induces miR-21 expression
In order to investigate the mechanism behind miR-21 ex-
pression we used a human fibroblast cell line, 1064SK.
1064SK cells with low basal levels of miR-21 were subjectedto PDGF-BB stimulation resulting in a strong increase in
miR-21 expression (Figure 5A). miR-21 expression is thus
indirectly or directly induced by PDGF signaling.
Inhibition of PDGF signaling causes down-regulation of
miR-21
If the sustained and increased expression of miR-21 in the
experimental glioma cells is caused by an up-regulation of
PDGF signaling, we would expect to find a down-regulation
of miR-21 upon inhibition of PDGF signaling. By using inhi-
bitors for the PDGFR itself and for known targets down-
stream of the PDGF receptor, we could verify that miR-21
was indeed decreased (Figure 5B). Treatment of p19Arf−/−
mouse glioma primary cultures with Gleevec (imatinib
mesylate), Rapamycin and U0126, all significantly reduced
the miR-21 levels, as shown by qPCR. A reduction could
also be shown after LY294002 (inhibiting PI3 kinase) treat-
ment, but this was not significant. The efficiency of the inhi-
bitors in decreasing their target´s protein phosphorylation
was observed compared to controls using Western blotting
(data not shown). We also investigated the effect on miR-21
expression in glioma-derived cancer initiating cells (GICs)
cultured as spheres derived from PDGFB-induced tumors in
neonatal Gtv-a mice [33]. When PDGF-BB expression was
inhibited by siRNA against PDGF-B we found a significant
Figure 3 Increased levels of miR-21 in mouse glioma cell lines
and glioma. A) Compared to normal mouse brain the different
mouse primary glioma cultures had an increased expression of
miR-21 as measured by Northern blot. U6 was used as a loading
control. In B) in situ hybridization of miR-21 in the tumor area of a
Gtv-a p16Ink4a−/−/p19Arf−/− mouse brain is presented, using a
digoxigenin-labeled miR-29b probe as an independent miRNA control.
In C) a Gtv-a p16Ink4a−/−/p19Arf−/− mouse brain could be seen,
showing miR-21 expression specifically to the tumor area adjacent to
the ventricle and the choroid plexus. T = tumor, and N=normal. Scale
bar is indicated in the figure and represents 50 μm.
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(Figure 5C). The reduction in miR-21 expression could be
coupled to a decrease in SOX2 expression, loss of tumor-
initiating ability of the cells and induction of oligodendro-
cyte differentiation [33].Elevated expression of miR-21 in human glioblastoma cell
lines
To verify our findings on mouse glioma, we used a panel of
human glioblastoma cell lines and analyzed them for miR-
21 expression by Northern blot analysis. All cell lines
expressed miR-21 at considerably higher levels than 1064SK
used as control, in accordance with previous publications
[9]. The extent of miR-21 expression varied between differ-
ent cell lines, U251MG revealed the highest expression and
U87MG and LN18 the lowest (Figure 6A). Two of the cell
lines, U2987MG and Cl2:6, showed in vitro expression of
SOX2 [34]. Western blot analysis of these cell lines demon-
strated a decrease in SOX2 expression upon addition of
LNA-miR-21 (Figure 6B), which confirms the data obtained
from the mouse glioma cell lines. A similar effect was seen
in a low passage human glioma cell culture, U3001MG,
grown in serum-free stem cell medium (Figure 6C).
Growth inhibition and apoptosis were induced by
inhibition of miR-21
Suppression of miR-21 in human cell lines has previously
been shown to result in apoptosis [9]. We investigated
whether a similar response was elicited in primary mouse
tumor cultures. Several apoptotic measurements were per-
formed upon miR-21 knockdown. Cell cycle analysis revealed
a strong increase in the SubG1-fraction (data not shown).
Furthermore, AnnexinV-staining showed a five-fold increase
in the number of apoptotic cells after repression of miR-21
by LNA-miR-21 both in an p16Ink4a/p19Arf double knockout
mouse glioma cell culture as well as in the human glioblast-
oma cell line LN18 (Figure 7A). The induction of apoptosis
could also be demonstrated by measuring the amount of
cleaved Caspase-3, an apoptotic marker. Western blot ana-
lysis supported induction of apoptosis by showing that loss
of miR-21 through LNA-miR-21 treatment increased the
amount of cleaved and activated Caspase-3. In Figure 7B the
result for a panel of primary mouse glioma cultures, the low
passage human glioma cell culture (U3001MG), and two
human glioblastoma cell lines (Cl2:6 and U2987MG) are
presented.
Discussion
Our data show that miR-21 is expressed during normal em-
bryogenesis and is tightly regulated in normal mouse devel-
opment. In mouse brain at E18, miR-21 was highly
expressed in areas known to contain a large number of
neural/glial progenitor cells, viz. hippocampus, dentate gyrus
and outer rim of the cortex. This pattern of miR-21 expres-
sion was sustained in the newborn brain but at P7, the ex-
pression was abolished and no expression could be found in
the adult brain. The finding that miR-21 is expressed in the
immature brain, but not in the adult tissue, indicates that
miR-21 is of developmental importance with a controlled
and restricted expression. Its overlapping expression with
Figure 4 In situ hybridization and IHC, showing similar expression pattern for miR-21, SOX2, and the tumor cell marker OLIG2.
Inhibition of miR-21 causes a decrease in SOX2 expression. A) Serial paraffin coronal sections of a Gtv-a p16Ink4a−/−/p19Arf−/− mouse brain
showing overlapping expression of miR-21, SOX2, and OLIG2. Scale bar is indicated in the figure and represents 50 μm. Western blot analysis,
demonstrating a decreased expression of the stem cell transcription factor SOX2, after LNA-miR-21 in p19Arf−/− mouse primary glioma cultures is
shown in B). GAPDH was used as a loading control.
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strated to be involved in the proliferation and/or mainten-
ance of neural stem cells in the developing brain [43,44],
indicating miR-21 to share these functions. We went on in-
vestigating brain tumors and showed that miR-21 is overex-
pressed in glioma tissue and primary cultures established
from RCAS/PDGFB-induced mouse gliomas, mimicking
human high grade gliomas. The expression of miR-21 in
PDGFB-induced mouse glioma was confined to the tumor
areas as shown by in situ hybridization. SOX2 has previously
been shown to be involved in the maintenance of stem cellFigure 5 PDGF-BB stimulation of normal fibroblasts resulted in increa
glioma cells caused a decrease of miR-21. Inhibition of PDGF signaling
initiating cells cultured as spheres, respectively. (A) Up-regulation of miR-21
treatment with PDGF-BB. U6 was used as a loading control. (B) miR-21 leve
cells with a panel of inhibitors. Bars represent mean values from two indep
statistical significance (p < 0.05) from Student´s t-test. (C) The expression lev
21 values were normalized to miR-16 and represent mean values from five
indicates statistical significance (p < 0.05) from Student´s t-test.properties and prevention of differentiation [45]. When per-
forming IHC staining of mouse brain tumors, an almost
complete overlap between SOX2 and miR-21 expression
could be seen. And although the role of miRNAs in stem
cell biology has not been fully explored, there is emerging
evidence suggesting posttranscriptional regulation of genes
as an important step in stem cell biology [46,47]. Tumor-
initiating cells or cancer stem cells have been found in many
types of cancers. These cells have been thought to represent
the radiotherapy and drug-resistant cell population [48,49].
When studying embryonic stem cells, siRNA against thesed expression of miR-21 whereas inhibition of PDGF signaling in
causes a decrease of miR-21 in a glioma cell culture and glioma
expression could be seen, using Northern blot, in 1064SK cells after
ls, normalized to miR-16, after inhibition of PDGF signaling in p19Arf−/−
endent experiments. SEMs are indicated in the figure and * indicates
el of miR-21 after si-PDGF-BB was analyzed by qPCR in TC1 cells. miR-
independent experiments. SEMs are indicated in the figure and *
Figure 6 Elevated expression of miR-21 in human glioblastoma cell lines and down regulation of SOX2 upon miR-21 knock down. A)
Human glioblastoma cell lines revealed a higher expression of miR-21 compared to the normal fibroblast cell line, 1064SK, as shown by Northern
blot analysis. U6 was used as a loading control. Western blot analysis showing a decreased expression of SOX2, after LNA-miR-21 in the human
glioblastoma cell lines U2987MG and Cl2:6 (B), and in human glioblastoma primary culture, U3001MG (C). GAPDH was used as a loading control.
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http://www.biomedcentral.com/1471-2407/12/378DNA-binding protein REST resulted in an increased expres-
sion of miR-21 accompanied by a reduced expression of
SOX2 and thereby a suppression of self-renewal [50,51]. In
this paper we reveal that siRNA-mediated knockdown of
miR-21 led to a significant reduction of SOX2 in both
mouse and human glioma cells. The discrepancy between
Singh et al. [51] and our results indicate that miRNA ex-
pression pattern, as well as downstream effects, differ inFigure 7 Inhibition of miR-21 mediated apoptosis in both mouse and
and human glioma cells undergo apoptosis upon miR-21 inhibition by usin
cell lines (left), the human glioblastoma primary culture U3001MG (center),
showed an increased level of cleaved Caspase-3 after LNA-miR-21 as comp
29b) as shown by Western blot analysis. GAPDH was used as a loading condifferent cell types depending on cellular context and the
available mRNA targets. Our findings suggest that miR-21
indirectly sustains the SOX2 expression and thereby is
involved in the maintenance of the glial progenitor/stem cell
phenotype. These functions are then recapitulated in the gli-
oma cells, in the present experimental mouse glioma system,
most likely caused by induced PDGF-BB expression. One
might consider that PDGFB-induced tumor developmenthuman tumor cells. A) AnnexinV staining showing that both mouse
g LNA-miR-21 as compared to si-control. B) A panel of mouse glioma
and the human glioblastoma cell lines Cl2:6 and U2987MG (right)
ared to si-control and two independent miRNAs (miR-29a and miR-
trol.
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http://www.biomedcentral.com/1471-2407/12/378involves activation of single or multiple signaling pathways
leading to continuous expression of miR-21, followed by an
increased expression of SOX2, thereby keeping the cell in a
progenitor/stem cell stage which protects them from under-
going apoptosis. Recent data from Bao et al. support such a
view of miR-21 as a mediator of the cancer stem cell pheno-
type [52]. Upon direct knockdown of miR-21 in tumor
cells, addicted to miR-21 expression, apoptosis is induced
[9] and Figure 7 in this paper. However, one cannot ex-
clude other mechanisms for tumor inhibition upon miR-21
suppression. For example, PDGF-B inhibition that causes
down-regulation of miR-21 (Figure 5C) is also known to
differentiate PDGFB-driven mouse brain tumor cells along
the oligodendrocyte lineage [33]. Specific mechanisms for
miR-21 regulation have been suggested in breast cancer as
well as lung cancer [53,54]. Here, we investigated the role
for the PDGF signaling pathway on miR-21 regulation in
glioma. By using a panel of inhibitors of PDGF signaling,
we could conclude that PDGF-BB and PDGFR-α signaling
drives miR-21 expression in primary mouse glioma cul-
tures. Likewise, si-PDGF-BB treatment of a primary mouse
glioma sphere culture resulted in a down-regulation of miR-
21, followed by a decrease in the number of spheres, further
strengthening the notion that miR-21 is indeed driven by
PDGF-BB signaling in these tumor cells. Shao et al. recently
described PDGF-AA and PDGF-BB to regulate a number of
miRNAs in the glioblastoma cell line U118, highlighting the
role of PDGF signaling in the alteration of miRNAs and
tumor development and progression [55].
Specific mechanisms for miR-21 regulation have been
suggested in breast cancer as well as lung cancer [53,54].
Here, we investigated the role for the PDGF-signaling path-
way on miR-21 regulation in glioma. By using a panel of
inhibitors of PDGF-signaling, we could conclude that PDGF-
BB and PDGFR-α signaling drives miR-21 expression in
primary mouse glioma cultures. Likewise, si-PDGF-BB treat-
ment of a primary mouse glioma sphere culture resulted in a
down-regulation of miR-21, followed by a decrease in the
number of spheres, further strengthening the notion that
miR-21 is indeed driven by PDGF-BB signaling in these
tumor cells. Shao et al. recently described PDGF-AA and
PDGF-BB to regulate a number of miRNAs in the glioblast-
oma cell line U118, high-lighting the role of PDGF-signaling
in the alteration of miRNAs and tumor development and
progession [55].
Conclusions
We show that miR-21 and SOX2 are co-expressed during
mouse brain development and subsequently down-regulated
in the adult mouse brain. An elevated expression of miR-21
was found in PDGFB-induced mouse glioma. Knockdown
of miR-21 with an LNA-modified siRNA or suppression of
miR-21 through PDGF inhibition was accompanied by a de-
crease in SOX2. Our data suggest that miR-21 regulatesSOX2 and is important in maintaining PDGF-driven brain
tumors that constitute the large proneural subgroup of
human malignant glioma [56]. The recently published data
revealing that withdrawal of miR-21 in a mouse model
leads to complete regression of tumors [13], make miR-21
a promising therapeutic target, particularly in glioblastoma
where effective treatment modalities are still lacking.
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